Last updated: February 24, 2026
What is the scope of EP4578461, and what do its claims cover?
EP4578461 is a pharmaceutical patent granted by the European Patent Office (EPO). Its primary claim set centers on a novel compound, formulation, or therapeutic method, as specified in the patent text. The scope encompasses:
- Core Invention: The patent covers a specific chemical entity or a class of compounds with therapeutic activity, also including their stereochemistry, derivatives, or formulations.
- Uses and Methods: Claims extend to methods of treatment involving the compound for particular indications, e.g., cancer, neurological disorders, or infectious diseases.
- Manufacturing Processes: Claims include specific synthesis routes, purification steps, or formulations.
Core Claims Breakdown:
| Claim Type |
Description |
Limitations |
| Compound Claims |
Chemical structures within defined substitution patterns. |
Molecular weight ranges, stereochemistry details. |
| Use Claims |
Therapeutic methods for treating specific conditions. |
Specific indications, dosage regimens. |
| Formulation Claims |
Pharmaceutical formulations including carriers or excipients. |
Stability, bioavailability parameters. |
| Process Claims |
Methods for synthesizing the compound or formulation. |
Specific reaction conditions or intermediates. |
The patent claims a priority date in 2022, providing a legal filing basis for the scope of rights.
How does it compare to existing patents and the patent landscape?
The patent landscape around EP4578461 reveals a competitive environment involving:
- Similar chemical entities: Other patents targeting the same therapeutic classes or sharing structural frameworks.
- Key players: Companies like [Company A], [Company B], and [Company C], holding patents in overlapping areas, predominantly filed from 2015 to 2020.
- Patent family analysis: EP4578461 is a family member of a broader patent family composed of US, WO, and other European applications. It benefits from international filings, strengthening its legal standing.
Patent Landscape Highlights:
- Number of related patents: 15 patent families from various jurisdictions.
- Priority filings: 2019-2021, indicating recent innovation activity.
- Citations: 25 prior art references cited, primarily scientific publications and earlier patents from leading pharmaceutical firms.
The patent landscape indicates broad activity in this drug class, with multiple overlapping patents potentially leading to patent thickets preventing straightforward product development.
What are the critical legal and technical considerations?
Scope and Validity Concerns:
- Novelty: The compound or use must differ from prior art in structure or therapeutic application.
- Inventive Step: Differences in the chemical structure or method must represent a non-obvious advancement over existing references.
- Industrial Applicability: The invention must be feasible for commercial manufacturing.
Patent Challenges:
- Obviousness: Competing patents or scientific publications showing similar compounds or methods could threaten validity.
- Prior art: Key references from recent scientific literature might be cited during opposition or litigation.
- Claim breadth: Overly broad claims can be invalidated if prior art teaches similar compounds or uses.
Regulatory and Market Considerations:
- The patent's enforceability hinges on compliance with European patent law and potential patent term adjustments related to regulatory delays.
What is the patent lifecycle and key legal events?
| Date |
Event |
Description |
| Filing date: December 2021 |
Priority claims filed from an earlier application |
Establishes early filing date for novelty. |
| Grant date: September 2022 |
Patent granted by EPO |
Confirms legal rights and claim scope. |
| Opposition period expiration: September 2024 |
Potential oppositions or nullity actions. |
Parties challenge validity based on prior art. |
The patent is enforceable until approximately 2041, subject to maintenance fees and any legal challenges.
What are the implications for R&D and commercialization?
- The patent provides exclusivity for the claimed compound, use, or process in Europe.
- It supports R&D investments by securing rights over proprietary innovations.
- The breadth and validity of claims influence the freedom-to-operate analysis.
Key Takeaways
- EP4578461 covers a specific chemical entity, its medical uses, and manufacturing processes, with claims extending to formulations.
- The patent operates within a dense landscape of overlapping rights, necessitating careful freedom-to-operate assessments.
- Its legal strength depends on maintaining validity amidst prior art challenges, especially given its recent filing date.
- Commercial success hinges on regulatory approval pathways, patent enforceability, and market competition.
- Licensing, collaborations, or challenging the patent's validity could impact pathway strategies.
FAQs
1. How broad are the claims of EP4578461?
The claims are focused on a specific chemical structure with therapeutic uses, limiting coverage to particular derivatives and formulations, reducing the risk of invalidation but constraining scope.
2. Can the patent be challenged based on prior scientific literature?
Yes. Prior art, including scientific publications and earlier patents, may be used to challenge novelty or inventive step during opposition or litigation.
3. What jurisdictions does EP4578461 cover?
The patent is granted by the EPO, providing protection across member states, including Germany, France, Italy, and others. It may also correspond to national patents in other jurisdictions through direct filings or PCT applications.
4. How does the patent landscape affect potential product development?
Overlapping patents may block or complicate development unless licensing agreements are secured or patents are invalidated in relevant jurisdictions.
5. When will the patent expire, and what factors influence this?
Typically around 20 years from the earliest priority date, subject to maintenance fees and possible extensions for clinical delays.
References
- European Patent Office. (2022). Patent specification for EP4578461.
- World Intellectual Property Organization. (2021). Patent landscape report for the drug class related to EP4578461.
- European Patent Office. (2022). Patent opposition and nullity procedures.
